Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

摘要: Objectives The purpose of this study was to compare the incidence new-onset diabetes (NOD) with cardiovascular (CV) event reduction at different levels NOD risk. Background Statins reduce number CV events but increase NOD. We previously reported that 4 factors independently predicted NOD: fasting blood glucose >100 mg/dl, triglycerides >150 body mass index >30 kg/m2, and history hypertension. Methods compared among 15,056 patients coronary disease without baseline in TNT (Treating New Targets) (n = 7,595) IDEAL (Incremental Decrease Endpoints Through Aggressive Lipid Lowering) 7,461) trials. included heart death, myocardial infarction, stroke, resuscitated cardiac arrest. Results Among 8,825 0 1 aforementioned risk baseline, developed 142 4,407 atorvastatin 80 mg group 148 4,418 10 simvastatin 20 40 groups (3.22% vs. 3.35%; hazard ratio [HR]: 0.97; 95% confidence intervals [CI]: 0.77 1.22). remaining 6,231 2 factors, 448 3,128 368 3,103 lower-dose (14.3% 11.9%; HR: 1.24; CI: 1.08 1.42; p 0.0027). significantly reduced both groups. Conclusions Compared statin therapy, mg/day did not did, by 24%, factors.